General Information of the Drug (ID: M6APDG02896)
Name
Nicaraven
Synonyms
AVS; Antevan; Antevas
    Click to Show/Hide
Status
Phase 3
Structure
Formula
C15H16N4O2
InChI
1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)
InChIKey
KTXBOOWDLPUROC-UHFFFAOYSA-N
PubChem CID
71234
TTD Drug ID
D0Z2UW
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Poly [ADP-ribose] polymerase 1 (PARP1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Nicaraven. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nicaraven through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Nicaraven. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Nicaraven through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
References
Ref 1 METTL3 promotes oxaliplatin resistance of gastric cancer CD133+?stem cells by promoting PARP1 mRNA stability. Cell Mol Life Sci. 2022 Feb 18;79(3):135. doi: 10.1007/s00018-022-04129-0.
Ref 2 Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3. doi: 10.1021/jm0255769.